

Caroline Palm-Apergi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8251743/publications.pdf>

Version: 2024-02-01

10
papers

125
citations

1477746

6
h-index

1473754

9
g-index

10
all docs

10
docs citations

10
times ranked

198
citing authors

#	ARTICLE	IF	CITATIONS
1	Polo-like kinases and acute leukemia. <i>Oncogene</i> , 2019, 38, 1-16.	2.6	54
2	RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients. <i>Journal of Controlled Release</i> , 2017, 261, 199-206.	4.8	17
3	Identification of novel small molecules that inhibit STAT3-dependent transcription and function. <i>PLoS ONE</i> , 2017, 12, e0178844.	1.1	17
4	Targeting Plk1 with siRNAs in primary cells from pediatric B-cell acute lymphoblastic leukemia patients. <i>Scientific Reports</i> , 2020, 10, 2688.	1.6	11
5	STAT3 is activated in multicellular spheroids of colon carcinoma cells and mediates expression of IRF9 and interferon stimulated genes. <i>Scientific Reports</i> , 2019, 9, 536.	1.6	9
6	RNAi prodrugs decrease elevated mRNA levels of Polo-like kinase 1 in ex vivo cultured primary cells from pediatric acute myeloid leukemia patients. <i>FASEB Journal</i> , 2021, 35, e21476.	0.2	6
7	Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib. <i>FASEB Journal</i> , 2021, 35, e21741.	0.2	5
8	Protein Delivery by PTDs/CPPs. <i>Methods in Molecular Biology</i> , 2022, 2383, 257-264.	0.4	4
9	Small-molecule inhibitors for targeting polo-like kinase 1. <i>Future Medicinal Chemistry</i> , 2020, 12, 1457-1460.	1.1	2
10	Designing siRNA and Evaluating Its Effect on RNA Targets Using qPCR and Western Blot. <i>Methods in Molecular Biology</i> , 2019, 2036, 53-72.	0.4	0